Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) will release first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the U.S. market open. Management will host a live webcast at 8:00 a.m. Eastern Time to review financial and operating results, accessible via the company Investor Relations website.
The live webcast is recommended to be accessed by registering at least 15 minutes early and will be available on-demand about two hours after the live event.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MDGL
On the day this news was published, MDGL gained 0.81%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MDGL is modestly higher (0.11%) on an earnings-date notice while close peers show mixed, mostly small moves, and no names are in the momentum scanner, indicating a stock-specific posture.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Earnings date announcement | Neutral | +0.1% | Set Q4 and full-year 2025 results date and webcast details. |
Prior earnings-date scheduling news produced a very small price move, suggesting these notices have been low-volatility catalysts.
This announcement schedules Madrigal’s first‑quarter 2026 results and webcast, similar to its prior notice on Feb. 2, 2026 for fourth‑quarter and full‑year 2025 results. That earlier earnings‑date press release led to a modest 0.09% move. Around that period, Madrigal reported substantial 2025 net sales and cash, and continued to issue employee inducement equity awards and participate in healthcare conferences, signaling steady operational and investor‑relations communication.
Historical Comparison
Past earnings-date news for MDGL led to a muted 0.09% move, so this new scheduling update closely mirrors prior low-volatility reactions.
Madrigal maintains a consistent pattern of pre-announcing earnings dates and hosting morning webcasts for financial updates.
Market Pulse Summary
This announcement sets the date and time for Madrigal’s first‑quarter 2026 results and webcast, continuing its practice of early earnings scheduling. Investors can monitor this event alongside the company’s prior full‑year 2025 results and recent operational updates to gauge continuity in sales, cash position, and strategic progress. Attention will likely center on how Q1 performance compares to the strong 2025 baseline already disclosed.
AI-generated analysis. Not financial advice.
CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com